Top

Published in:

01-10-2020 | Prostate Cancer | Original Article

External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers

Authors: Luca Cindolo, Riccardo Bertolo, Andrea Minervini, Francesco Sessa, Gianluca Muto, Pierluigi Bove, Matteo Vittori, Giorgio Bozzini, Pietro Castellan, Filippo Mugavero, Mario Falsaperla, Luigi Schips, Antonio Celia, Maida Bada, Angelo Porreca, Antonio Pastore, Yazan Al Salhi, Marco Giampaoli, Giovanni Novella, Riccardo Rizzetto, Nicoló Trabacchin, Guglielmo Mantica, Giovannalberto Pini, Riccardo Lombardo, Andrea Tubaro, Alessandro Antonelli, Cosimo De Nunzio

Published in: World Journal of Urology | Issue 10/2020

Abstract

Purpose

Recently, the Cormio et al. nomogram has been developed to predict prostate cancer (PCa) and clinically significant PCa using benign prostatic obstruction parameters. The aim of the present study was to externally validate the nomogram in a multicentric cohort.

Methods

Between 2013 and 2019, patients scheduled for ultrasound-guided prostate biopsy were prospectively enrolled at 11 Italian institutions. Demographic, clinical and histological data were collected and analysed. Discrimination and calibration of Cormio nomogram were assessed with the receiver operator characteristics (ROC) curve and calibration plots. The clinical net benefit of the nomogram was assessed with decision curve analysis. Clinically significant PCa was defined as ISUP grade group > 1.

Results

After accounting for inclusion criteria, 1377 patients were analysed. 816/1377 (59%) had cancer at final pathology (574/816, 70%, clinically significant PCa). Multivariable analysis showed age, prostate volume, DRE and post-voided residual volume as independent predictors of any PCa. Discrimination of the nomogram for cancer was 0.70 on ROC analysis. Calibration of the nomogram was excellent (p = 0.94) and the nomogram presented a net benefit in the 40–80% range of probabilities. Multivariable analysis for predictors of clinically significant PCa found age, PSA, prostate volume and DRE as independent variables. Discrimination of the nomogram was 0.73. Calibration was poor (p = 0.001) and the nomogram presented a net benefit in the 25–75% range of probabilities.

Conclusion

We confirmed that the Cormio nomogram can be used to predict the risk of PCa in patients at increased risk. Implementation of the nomogram in clinical practice will better define its role in the patient’s counselling before prostate biopsy.

Available only for authorised users

EAU guidelines: prostate cancer (2019). https://uroweb.org/guideline/prostate-cancer/#5. Accessed 17 Aug 2019

Serag H, Banerjee S, Saeb-Parsy K, Irving S, Wright K, Stearn S et al (2012) Risk profiles of prostate cancers identified from UK primary care using national referral guidelines. Br J Cancer 106:436–439. https://doi.org/10.1038/bjc.2011.596CrossRefPubMedPubMedCentral

Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ (2012) Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial. BJU Int 110:1654–1660. https://doi.org/10.1111/j.1464-410X.2012.11481.xCrossRefPubMed

Louie KS, Seigneurin A, Cathcart P, Sasieni P (2015) Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol 26:848–864. https://doi.org/10.1093/annonc/mdu525CrossRefPubMed

Vedder MM, Bekker-Grob EW, Lilja HG, Vickers AJ, Leenders GJ, Steyerberg EW, Roobol MJ (2014) The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol 66(6):1109–1115CrossRef

Leyten GH, Hessels D, Jannink SA et al (2014) Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 65(3):534–542CrossRef

Boegemann M, Stephan C, Cammann H, Vincendeau S, Houlgatte A, Jung K, Blanchet JS, Semjonow A (2016) The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged %3c/=65 years. BJU Int 117(1):72–79. https://doi.org/10.1111/bju.13139(Epub 2015 May 24)CrossRefPubMed

Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, Davis M, Scardino PT, Donovan J, Neal DE, Lilja H, Hamdy FC (2015) Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv095CrossRefPubMedPubMedCentral

Falagario UG, Martini A, Wajswol E et al (2019) Avoiding unnecessary magnetic resonance imaging (MRI) and biopsies: negative and positive predictive value of MRI according to prostate-specific antigen density, 4Kscore and risk calculators. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2019.08.015(Epub ahead of print)CrossRefPubMed

10.

Cormio L, Cindolo L, Troiano F et al (2018) Development and internal validation of novel nomograms based on benign prostatic obstruction-related parameters to predict the risk of prostate cancer at first prostate biopsy. Front Oncol 8:438. https://doi.org/10.3389/fonc.2018.00438(eCollection 2018)CrossRefPubMedPubMedCentral

11.

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA et al (2016) The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244–252. https://doi.org/10.1097/PAS.0000000000000530CrossRefPubMed

12.

Antonelli A, Fugini AV, Tardanico R, Giovanessi L, Zambolin T, Simeone C (2014) The percentage of core involved by cancer is the best predictor of insignificant prostate cancer, according to an updated definition (tumor volume up to 2.5 cm3): analysis of a cohort of 210 consecutive patients with low-risk disease. Urology 83(1):28–32CrossRef

13.

Autorino R, De Sio M, Di Lorenzo G et al (2005) How to decrease pain during transrectal ultrasound guided prostate biopsy: a look at the literature. J Urol 174(6):2091–2097CrossRef

14.

Azevedo N, Verbeek JFM, Nieboer D, Bangma CH, Roobol MJ (2018) Head-to-head comparison of prostate cáncer risk calculators predicting biopsy outcome. Transl Androl Urol 7(1):18–26. https://doi.org/10.21037/tau.2017.12.21CrossRefPubMedPubMedCentral

15.

Schoots IG, Padhani AR (2019) Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated? World J Urol. https://doi.org/10.1007/s00345-019-02899-0(Epub ahead of print)CrossRefPubMedPubMedCentral

16.

Cormio L, Lucarelli G, Selvaggio O et al (2016) Absence of bladder outlet obstruction is an independent risk factor for prostate cancer in men undergoing prostate biopsy. Medicine (Baltimore) 95(7):e2551CrossRef

17.

Cormio L, Lucarelli G, Netti GS et al (2015) Post-void residual urinary volume is an independent predictor of biopsy results in men at risk for prostate cancer. Anticancer Res 35(4):2175–2182PubMed

18.

Cicione A, Cormio L, Cantiello F et al (2017) Presence and severity of lower urinary tract symptoms are inversely correlated with the risk of prostate cancer on prostate biopsy. Minerva Urol Nefrol 69(5):486–492PubMed

19.

Kranse R, Roobol M, Schroder FH (2008) A graphical device to represent the outcomes of a logistic regression analysis. Prostate 68:1674–1680CrossRef

20.

Dong F, Kattan MW, Steyerberg EW et al (2008) Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 180(1):150–154. https://doi.org/10.1016/j.juro.2008.03.053(discussion 154, Epub 2008 May 15)CrossRefPubMed

21.

Roobol MJ, Schröder FH, Hugosson J et al (2012) Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol 30(2):149–155. https://doi.org/10.1007/s00345-011-0804-y(Epub 2011 Dec 28)CrossRefPubMed

22.

Rove KO, Crawford ED (2012) Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts. World J Urol 30(2):137–142. https://doi.org/10.1007/s00345-011-0799-4(Epub 2011 Nov 25)CrossRefPubMed

23.

Moreira DM, Freitas ODM, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ (2017) The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens. Prostate Cancer Prostatic Dis 20:413–417. https://doi.org/10.1038/pcan.2017.30CrossRefPubMed

24.

De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F et al (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60:106–117. https://doi.org/10.1016/j.eururo.2011.03.055CrossRefPubMed

25.

Falagario U, Selvaggio O, Carrieri G et al (2018) Prostatic inflammation is associated with benign prostatic hyperplasia rather than prostate cancer. J Gerontol Geriatr 2018(4):178–182

26.

Drost FH, Osses DF, Nieboer D et al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 4:CD012663. https://doi.org/10.1002/14651858.CD012663.pub2CrossRefPubMed

27.

van der Leest M, Cornel E, Israël B et al (2019) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol 75(4):570–578. https://doi.org/10.1016/j.eururo.2018.11.023(Epub 2018 Nov 23)CrossRefPubMed

28.

Padhani AR, Barentsz J, Villeirs G et al (2019) PI-RADS Steering Committee: the PI-RADS multiparametric MRI and MRI-directed biopsy pathway. Radiology 292(2):464–474. https://doi.org/10.1148/radiol.2019182946 (Epub 2019 Jun 11)CrossRefPubMedPubMedCentral

29.

Thompson IM, Ankerst DP, Chi C et al (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 98:529–534CrossRef

Title: External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers
Authors: Luca Cindolo
Riccardo Bertolo
Andrea Minervini
Francesco Sessa
Gianluca Muto
Pierluigi Bove
Matteo Vittori
Giorgio Bozzini
Pietro Castellan
Filippo Mugavero
Mario Falsaperla
Luigi Schips
Antonio Celia
Maida Bada
Angelo Porreca
Antonio Pastore
Yazan Al Salhi
Marco Giampaoli
Giovanni Novella
Riccardo Rizzetto
Nicoló Trabacchin
Guglielmo Mantica
Giovannalberto Pini
Riccardo Lombardo
Andrea Tubaro
Alessandro Antonelli
Cosimo De Nunzio
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: World Journal of Urology / Issue 10/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-03058-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2020

3D printing technology and its role in urological training

Urinary metabolites identified using metabolomic analysis as potential biomarkers of nocturia in elderly men

The era of the digital natives is approaching: Insights into online peer-to-peer support for persons affected by prostate cancer

Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis

Application of artificial neural networks for automated analysis of cystoscopic images: a review of the current status and future prospects

Transurethral prostate surgery as a preventive method against progression of chronic kidney disease in patients with urodynamically proven bladder outlet obstruction